SCHEMBL1342834

SCHEMBL1342834

CC(C)COc1ccccc1NC(=O)CC(=O)Nc1nc(CC(=O)O)c(Sc2ncc[nH]2)s1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 4/20 0.38
CASP1 P29466 2/20 0.38
HSD17B10 Q99714 1/20 0.38
GAA P10253 2/20 0.36
MPO P05164 1/20 0.36
POLB P06746 3/20 0.36
KDM4E B2RXH2 4/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
ALDH1A1 P00352 4/20 0.34
LMNA P02545 3/20 0.34
MAPT P10636 3/20 0.34
MEN1 O00255 1/20 0.34
ALOX12 P18054 1/20 0.34
KMT2A Q03164 1/20 0.34
CYP2C19 P33261 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
PRMT5 O14744 1/20 0.34
WDR77 Q9BQA1 1/20 0.34
HPGD P15428 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1343330 0.93 TSHR (0.35) TSHRCASP1HSD17B10GAAMPO
SCHEMBL1341247 0.91 GCK (0.38) TSHRCASP1HSD17B10GAAPOLB
SCHEMBL1343678 0.90 MAPT (0.35) HSD17B10GAAPOLBSMN1; SMN2LMNA
SCHEMBL1343027 0.88 HSD17B10 (0.36) TSHRCASP1HSD17B10GAAMPO
SCHEMBL1342875 0.87 TSHR (0.41) TSHRCASP1HSD17B10GAAMPO
SCHEMBL1341013 0.86 GCK (0.41) GAAPOLBKDM4ESMN1; SMN2ALDH1A1
SCHEMBL1342575 0.85 CYP2C19 (0.41) TSHRHSD17B10GAAPOLBKDM4E
SCHEMBL1342804 0.83 GCK (0.38)
SCHEMBL1342841 0.83 MAPT (0.32) HSD17B10POLBKDM4ESMN1; SMN2MAPT
SCHEMBL1343024 0.83 HSD17B10 (0.36) TSHRCASP1HSD17B10GAAMPO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8063081-B2 N-(2-Phenoxyphenyl)-N'-(thiazol-2-yl)urea; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-11-22 US disclosed
US-7897628-B2 {2-[3-(4-Methyl-2-[2-methypropoxy]phenyl)-ureido]-thiazol-4-yl}-acetic acid ethyl ester; glucokinase inhibitor; antidiabetic, hypoglycemic agent; activators of glucokinase NOVO NORDISK A/S (DK) 2011-03-01 US disclosed
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents VTV THERAPEUTICS LLC 2004-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122235-A1 Aryl carbonyl derivatives as therapeutic agents GCK, GCKR, PDK2 TSHR 2745/4885CASP1 1541/4885HSD17B10 611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.